The presence of an obstructive sleep apnea-hypopnea syndrome (OSAHS) is a perfectly identified cardiovascular and metabolic risk factor responsible for excess mortality in patients with severe OSAHS, while life expectancy, when the SAHOS is treated by continuous positive airway pressure (CPAP) is close to that of the general population. It also represents a factor of excess mortality, little known and poorly explored, in relation to morbidity and mortality occurring during the perioperative period accompanying any general anesthesia.
Study Type
OBSERVATIONAL
Enrollment
48
Chu de Poitiers
Poitiers, France
Evaluate rate of respiratory complications with moderate sleep apnea syndrome with continuous positive airway pressure treatment
Time frame: 7 days
Evaluate rate of respiratory complications with moderate sleep apnea syndrome without continuous positive airway pressure treatment
Time frame: 7 days
Evaluate rate of cardiovascular complications with moderate sleep apnea syndrome with continuous positive airway pressure treatment
Time frame: 7 days
Evaluate rate of cardiovascular complications with moderate sleep apnea syndrome without continuous positive airway pressure treatment
Time frame: 7 days
Evaluate tolerance and observance of continuous positive airway pressure treatment
Time frame: 7 days
Evaluate the feasibility of the ApneaLink
Time frame: 7 days
Evaluate the prevalence of obstructive sleep apnea-hypopnea syndrome patients to the severity level of the STOPBANG score,
Time frame: 7 days
Evaluate the duration and place of hospitalization during the post-surgical course
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.